Compositions and methods for enhancing drug delivery across biological membranes and tissues
First Claim
1. A method for delivery of a compound to the surface of, into or across a biological barrier, the method comprising contacting the barrier with a composition comprising the compound and a delivery-enhancing transporter, wherein the delivery-enhancing transporter comprises sufficient guanidino or amidino moieties to increase delivery of the compound into or across the barrier compared to delivery of the compound in the absence of the delivery-enhancing transporter.
2 Assignments
0 Petitions
Accused Products
Abstract
This invention provides compositions and methods for enhancing delivery of drugs and other agents across a biological barrier, including epithelial tissues such as the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 50 residues in length.
-
Citations
40 Claims
-
1. A method for delivery of a compound to the surface of, into or across a biological barrier, the method comprising contacting the barrier with a composition comprising the compound and a delivery-enhancing transporter,
wherein the delivery-enhancing transporter comprises sufficient guanidino or amidino moieties to increase delivery of the compound into or across the barrier compared to delivery of the compound in the absence of the delivery-enhancing transporter.
-
32. A composition comprising:
-
an effective amount of a biologically active agent;
a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase delivery of the biologically active agent across a biological barrier compared to the delivery of the biologically active agent in the absence of the transporter; and
a pharmaceutically acceptable carrier. - View Dependent Claims (33, 34, 35, 36, 37, 38, 39, 40)
-
Specification